Cellectar reports 8-year complete response in DLBCL patient using iopofosine

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. REGN
2. CRWD
3. LITE
4. AAPL
5. ABBV
6. MRVL
7. CL
8. TFII
9. LYB
10. RXRX

Go back to Cellectar reports 8-year complete response in DLBCL patient using iopofosine

Cellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131

October 27, 2026 7:15 AM EDT

Durable Complete Response Achieved with Single Administration of Iopofosine I 131 

Provides Additional Clinical Support for the Differentiated Mechanism of Action of Iopofosine I 131 and its Potential Utility Across a Range of B-cell Malignancies

FLORHAM PARK, N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today reported results from a case study highlighting a durable complete response in a heavily pretreated patient with diffuse large B-cell lymphoma... More